Dressing with increased apposition force

ABSTRACT

In some embodiments, a dressing assembly may include a dressing bolster, an interface seal, and a base layer. The dressing bolster may include a first side, a second side, and a periphery. The interface seal may be coupled at the periphery of the dressing bolster. The base layer may include a base layer flange configured to be coupled to the dressing and to extend beyond the periphery of the dressing bolster. The dressing assembly may be suitable for treating a tissue site with reduced pressure and for creating an apposition force between a first portion of the tissue site and a second portion of the tissue site. Other systems, apparatus, and methods are disclosed.

RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 15/755,498, filed Feb. 26, 2018, which is a U.S. National Stage Entry of PCT/US2016/047351, filed Aug. 17, 2016, which claims the benefit, under 35 USC 119(e), of the filing of U.S. Provisional Patent Application No. 62/212,787, entitled “Dressing with Increased Apposition Force,” filed Sep. 1, 2015, all of which are incorporated herein by reference for all purposes.

TECHNICAL FIELD

This disclosure relates generally to medical treatment systems and, more particularly, but not by way of limitation, to reduced pressure dressings, systems, and methods for treating a tissue site.

BACKGROUND

Clinical studies and practice have shown that reducing pressure in proximity to a tissue site can augment and accelerate growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but have been proven particularly advantageous for treating wounds. Regardless of the etiology of a wound, whether trauma, surgery, or another cause, proper care of the wound is important to the outcome. Treatment of wounds or other tissue with reduced pressure may be commonly referred to as “reduced-pressure therapy.” However, such treatment may also be known by other names including “negative-pressure therapy,” “negative-pressure wound therapy,” “vacuum therapy,” “vacuum-assisted closure,” and “topical negative-pressure,” for example. Reduced-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a tissue site. Together, these benefits can increase development of granulation tissue and reduce healing times.

Cost and complexity can limit the application of reduced-pressure therapy systems. Development and operation of therapy systems, components, and processes may benefit manufacturers, healthcare providers, and patients.

SUMMARY

In some illustrative embodiments, a system for treating a tissue site may include a dressing bolster, a comfort layer, an interface seal, a base layer, a sealing member, and a reduced-pressure source. The dressing bolster may include a first side, a second side, and a periphery. The comfort layer may include a first side and a second side. The first side of the comfort layer may be coupled to the second side of the dressing bolster. The interface seal may be coupled to the second side of the comfort layer. The base layer may include a base layer flange configured to be coupled to the dressing bolster and to extend beyond the periphery of the dressing bolster. The sealing member may be configured to cover the dressing bolster and to create a sealed space relative to the tissue site. The reduced-pressure source may be configured to be coupled in fluid communication with the sealed space.

In some illustrative embodiments, a dressing assembly may include a dressing bolster, an interface seal, a base layer, a sealing member, and an adhesive. The dressing bolster may include a first side, a second side, and a periphery. The interface seal may be coupled at the periphery of the dressing bolster. The base layer may include a base layer flange configured to be coupled to the dressing bolster and to extend beyond the periphery of the dressing bolster. The sealing member may be configured to cover at least a portion of the first side of the dressing bolster. The adhesive may be positioned at least between the sealing member and the base layer flange.

In some illustrative embodiments, a method for treating a tissue site may include providing a dressing bolster having a first side, a second side, and an edge defining an outer boundary of the dressing bolster. Further, the method may include positioning an interface seal between the second side of the dressing bolster and the tissue site at the edge of the dressing bolster. Further, the method may include coupling a base layer to the dressing bolster and to a tissue around the tissue site. Further, the method may include covering the first side of the dressing bolster with a sealing member to form a sealed space relative to the tissue site.

In some illustrative embodiments, a system for treating a tissue site may include a manifold, an interface seal, a base layer, and a drape. The manifold may include a first side, a second side, and a periphery. The interface seal may be positioned at the periphery of the manifold and on the second side of the manifold. The base layer may include a base layer flange configured to extend beyond the periphery of the manifold. The drape may be configured to cover the first side of the manifold and to create a sealed space relative to the tissue site.

In some illustrative embodiments, a dressing assembly may include a manifold, an interface seal, and a base layer. The manifold may include a first side, a second side, and a periphery. The interface seal may be coupled at the periphery of the manifold. The base layer may include a base layer flange configured to extend beyond the periphery of the manifold.

Other features and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a perspective view of an illustrative embodiment of a system for treating a tissue site;

FIG. 2 is a cross-section of a portion of an illustrative embodiment of a dressing assembly depicted in FIG. 1, taken along line 2-2;

FIG. 3 is a detail view, taken at reference FIG. 3 shown in FIG. 2, illustrating the dressing assembly of FIG. 1 positioned proximate to tissue surrounding the tissue site;

FIG. 4 is an exploded view of an illustrative embodiment of a sealing member, an adhesive, and a base layer depicted in FIG. 3;

FIGS. 5A-5C are perspective, cross-sectional views of a portion of an illustrative embodiment of a system for treating a tissue site being deployed at the tissue site;

FIG. 6 is a perspective view of another illustrative embodiment of a system for treating a tissue site;

FIG. 7 is a graph illustrating an increase in apposition force generated by an improved dressing assembly and system according to this disclosure.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

In the following detailed description of illustrative embodiments, reference is made to the accompanying drawings that form a part hereof. The illustrative embodiments are described in sufficient detail to enable those skilled in the art to practice the subject matter of this disclosure. Other embodiments may be utilized, and logical, structural, mechanical, electrical, and chemical changes may be made without departing from the scope of this disclosure. To avoid detail not necessary to enable those skilled in the art to practice the embodiments described herein, the description may omit certain information known to those skilled in the art. Therefore, the following detailed description is non-limiting, with the scope of the illustrative embodiments being defined by the appended claims.

Referring to FIGS. 1 and 2, presented is an illustrative, non-limiting embodiment of a treatment system 100 for treating a tissue site 102, such as a linear wound or an incision 104. The incision 104 is shown extending through or involving an epidermis 106, a dermis 108, and a subcutaneous tissue 110. The treatment system 100 may also be used with other tissue sites, and may be used with or without reduced pressure.

The treatment system 100 may include a dressing assembly 112. The dressing assembly 112 may include, without limitation, a dressing bolster 114. In some embodiments, the dressing bolster 114 may be a manifold 114. Further, elements of the dressing bolster 114 may be applicable to the manifold 114, and the dressing bolster 114 may be interchangeably referred to herein as the manifold 114. In addition to the dressing assembly 112, the treatment system 100 may include a sealing member 116 and a reduced-pressure subsystem 118. While the treatment system 100 is shown in the context of a reduced-pressure dressing over an incision 104, the treatment system 100 may be used on other tissue sites, including open wounds.

In some embodiments, the sealing member 116 may be a drape 116, and the sealing member 116 or the drape 116 may form part of the dressing assembly 112. The sealing member 116 may be configured to cover the dressing bolster 114 and to create a sealed space 119 relative to the tissue site 102, for example, between the sealing member 116 and the tissue site 102. Further, the sealing member 116 may cover other tissue, such as a portion of the epidermis 106, around or surrounding the tissue site 102 to provide the sealed space 119 between the sealing member 116 and the tissue site 102. The dressing bolster 114 may be positioned in the sealed space 119.

The reduced-pressure subsystem 118 may include a reduced-pressure source 144. The reduced-pressure source 144 may provide reduced pressure as a part of the treatment system 100, and may be configured to be coupled in fluid communication with the sealed space 119. For example, the reduced-pressure source 144 may be fluidly coupled to a conduit interface 138 by a delivery conduit 148. An aperture (not shown) may be formed on a portion of the sealing member 116 to allow fluid communication between the sealed space 119 and the reduced-pressure sourced 144 through the conduit interface 138 and the delivery conduit 148.

As used herein, “reduced pressure” may refer to a pressure less than the ambient pressure at a tissue site being subjected to treatment, such as the tissue site 102. The reduced pressure may be less than the atmospheric pressure. The reduced pressure may also be less than a hydrostatic pressure at a tissue site. Unless otherwise indicated, quantitative values of pressure stated herein are gauge pressures.

The reduced pressure delivered to the sealed space 119 and the dressing bolster 114 may be constant or varied, patterned or random, and may be delivered continuously or intermittently. Although the terms “vacuum” and “negative pressure” may be used to describe the pressure applied to a tissue site, the actual pressure applied to the tissue site may be more than the pressure normally associated with a complete vacuum. Consistent with the use herein, unless otherwise indicated, an increase in reduced pressure or vacuum pressure may refer to a relative reduction in absolute pressure.

The reduced-pressure source 144 may include a reservoir region 146, or canister region. An interposed membrane filter (not shown), such as a hydrophobic or oleophobic filter, may be interspersed between the reduced-pressure delivery conduit 148 and the reduced-pressure source 144. One or more devices, such as a representative device 150, may be fluidly coupled to the reduced-pressure delivery conduit 148. The representative device 150 may be, for example, another fluid reservoir, a collection member to hold exudates and other fluids removed, a pressure-feedback device, a volume detection system, a blood detection system, an infection detection system, a flow monitoring system, or a temperature monitoring system. Multiple representative devices 150 may be included. One or more of the representative devices 150 may be formed integrally with the reduced-pressure source 144.

The reduced-pressure source 144 may be any device for supplying a reduced pressure, such as a vacuum pump, wall suction, or other source. While the amount and nature of reduced pressure applied to a tissue site may vary according to the application, the reduced pressure may be, for example, between about −5 mm Hg (−667 Pa) to about −500 mm Hg (−66.7 kPa). In some embodiments, the reduced pressure may be between about −75 mm Hg (−9.9 kPa) to about −300 mm Hg (−39.9 kPa).

The reduced pressure developed by the reduced-pressure source 144 may be delivered through the delivery conduit 148 to the conduit interface 138. The conduit interface 138 may allow the reduced pressure to be delivered through the sealing member 116 to the dressing bolster 114. In some embodiments, the conduit interface 138 may provide fluid communication external to the sealing member 116 without the application of reduced pressure.

The dressing bolster 114 may have a first side 120, a periphery 121, and a second, inward-facing side 122. The second, inward-facing side 122 of the dressing bolster 114 may be configured to face the tissue site 102. The first side 120 of the dressing bolster 114 may be opposite the second, inward-facing side 122 such that the first side 120 may be configured to face outward or away from the tissue site 102. The periphery 121 of the dressing bolster 114 may define an outer boundary or lateral boundary of the dressing bolster 114 and the first side 120 and the second, inward-facing side 122 of the dressing bolster 114.

In some embodiments, the periphery 121 of the dressing bolster 114 may be an edge 121 of the dressing bolster 114. The edge 121 of the dressing bolster 114 may be a lateral edge positioned orthogonal relative to the second, inward-facing side 122 of the dressing bolster 114. The edge 121 of the dressing bolster 114 may also be a beveled edge or an angled edge. The angled or beveled edge may help distribute shear stress between the dressing bolster 114 and the epidermis 106 of a patient.

In some embodiments, the dressing bolster 114 may include one or more notches, recesses, or cuts, such as a notch 123. For example, the notch 123 may be a lateral or longitudinal cut in the dressing bolster 114 on the first side 120. The notch 123 may enhance the flexibility of the dressing bolster 114. Enhanced flexibility may be particularly useful for application of the dressing assembly 112 over a joint or other area of movement on a patient. The notch 123 may also take various shapes without limitation, such as, for example, hexagons, slits, or squares.

The dressing bolster 114 may be formed from any bolster material or manifold material capable of providing a vacuum space, or treatment space. For example, the dressing bolster 114 may be formed from a porous and permeable foam or foam-like material, a member formed with pathways, a graft, a gauze, or any combination thereof. Reduced pressure applied to the dressing bolster 114 may enhance the permeability of the dressing bolster 114.

The term “manifold” as used herein may refer to a substance or structure that may assist in applying reduced pressure to, delivering fluids to, or removing fluids from a tissue site. A manifold may include a plurality of flow channels or pathways. The plurality of flow channels may be interconnected to improve distribution of fluids provided to and removed from an area of tissue around the manifold. Examples of manifolds may include, without limitation, devices that have structural elements arranged to form flow channels, cellular foam, such as open-cell foam, porous tissue collections, and liquids, gels, and foams that include or cure to include flow channels.

In some embodiments, the dressing bolster 114 may be a reticulated, open-cell polyurethane or polyether foam that may be fluid permeable. One such foam material may be a VAC® GranuFoam® material available from Kinetic Concepts, Inc. (KCI) of San Antonio, Tex. The reticulated pores of the GranuFoam® material may be helpful in carrying out the manifold function, but as stated above, other materials may be utilized. A material with a higher or lower density than the GranuFoam® material may be desirable in some embodiments. This material may have, for example, a smaller pore size than the GranuFoam® material. Among the many possible materials, the following may be used without limitation: GranuFoam® material, FXI technical foam (www.fxi.com), gauze, a flexible channel-containing member, a graft, and other similar materials. In some embodiments, ionic silver may be added to the material, such as, for example, by a micro bonding process. Other substances, such as antimicrobial agents, may also be added to the material.

In some embodiments, the dressing assembly 112 may include a comfort layer 124 having a first side 126, a periphery 127, and a second, inward-facing side 128. In some embodiments, the comfort layer 124 may be an interface layer 124. Further, elements of the comfort layer 124 may be applicable to the interface layer 124, and the comfort layer 124 may be interchangeably referred to herein as the interface layer 124.

The second, inward-facing side 128 of the comfort layer 124 may be configured to face the tissue site 102. The first side 126 of the comfort layer 124 may be opposite the second, inward-facing side 128 such that the first side 126 may be configured to face outward or away from the tissue site 102. The periphery 127 of the comfort layer 124 may define an outer boundary or lateral boundary of the comfort layer 124 and the first side 126 and the second, inward-facing side 128 of the comfort layer 124. In some embodiments, the periphery 127 of the comfort layer 124 may be an edge 127 of the comfort layer 124.

The first side 126 of the comfort layer 124 may be coupled, for example, by a heat bond or other suitable technique to the second, inward-facing side 122 of the dressing bolster 114. In some embodiments, the periphery 127 of the comfort layer 124 may substantially correspond to, or be substantially aligned with, the periphery 121 of the dressing bolster 114. The comfort layer 124 may enhance patient comfort when the dressing bolster 114 is adjacent to the epidermis 106 of a patient. For example, in some embodiments, at least a portion of the second, inward-facing side 128 of the comfort layer 124 may be configured to directly contact the tissue site 102.

The comfort layer 124 may be any material suitable for preventing skin irritation and discomfort while allowing fluid transmission through the comfort layer 124. As non-limiting examples, a woven material, an elastic material, a polyester knit textile substrate, a nonwoven material, or a fenestrated film may be used. As another non-limiting example, an InterDry™ textile material from Milliken Chemical, a division of Milliken & Company, Inc. of Spartanburg, S.C., may be used. In some embodiments, the comfort layer 124 may include antimicrobial substances, such as silver.

In some embodiments, the dressing assembly 112 may include an interface seal 130. In some embodiments, the interface seal 130 may be a sealing ring 130. Further, elements of the interface seal 130 may be applicable to the sealing ring 130, and the interface seal 130 may be interchangeably referred to herein as the sealing ring 130. The interface seal 130 may enhance or otherwise provide a fluid seal at or around the tissue site 102, such as the incision 104. For example, a surface of the epidermis 106 may have recesses, cracks, wrinkles, or other discontinuities that may cause leaks. Moreover, folds, buckles, wrinkles, or other discontinuities may form in the sealing member 116 that can cause leaks. The interface seal 130 may help seal any such skin or sealing member discontinuities at or around the tissue site 102. Further, the interface seal 130 may also enhance the ability of the dressing assembly 112 to impart an apposition force to the tissue site 102, for example, for closing the incision 104, or otherwise moving portions of tissue toward one another at the tissue site 102.

The interface seal 130 may function as a two-sided gasket that may provide a seal between the dressing assembly 112 and the tissue site 102 and/or epidermis 106. For example, the interface seal 130 may provide a seal between the dressing bolster 114, the comfort layer 124, or the sealing member 116 and the tissue site 102 and/or epidermis 106. The interface seal 130 may also absorb perspiration or other fluids from the tissue site 102. Further, the interface seal 130 may distribute shear forces created, for example, by the application of reduced pressure at the interface of the dressing bolster 114 and the tissue site 102 and/or the epidermis 106.

The interface seal 130 may be adapted to be positioned between the dressing bolster 114 and the tissue site 102. For example, the interface seal 130 may be positioned between the second, inward-facing side 122 of the dressing bolster 114 and the tissue site 102. In some embodiments, the interface seal 130 may be coupled to the second, inward-facing side 122 of the dressing bolster 114.

In some embodiments, the interface seal 130 may be positioned at the periphery 121 of the dressing bolster 114, or coupled to the periphery 121 of the dressing bolster 114. Further, the interface seal 130 may be positioned between the dressing bolster 114 and tissue at or around the tissue site 102, such as the epidermis 106. Thus, in some embodiments, at least a portion of the interface seal 130 may be positioned around the periphery 121 of the dressing bolster 114 and a periphery of the tissue site 102. Further, in some embodiments, at least a portion of the interface seal 130 may substantially surround the periphery 121 of the dressing bolster 114 and a periphery of the tissue site 102.

In some embodiments, other layers or elements, such as the comfort layer 124, may be included with the dressing assembly 112 and positioned between the dressing bolster 114 and the interface seal 130. In such embodiments, at least a portion of the second, inward facing side 122 of the dressing bolster 114 and/or the second, inward-facing side 128 of the comfort layer 124 may be free of the interface seal 130 and configured to be positioned in fluid communication with the tissue site 102.

The interface seal 130 may be formed, as an illustrative example, by applying or bonding sealing material to the dressing bolster 114. The sealing material that may be used for the interface seal 130 may include hydrocolloids, hydrogels, silicone polymers (both crosslinked and uncrosslinked gels), and natural gums (xanthan, guar, cellulose). The sealing material may include other soft polymer gels, such as, for example, those based on polyurethanes, polyolefin gels, and acrylics.

The interface seal 130 may have a durometer, such as a material softness or hardness, between about 20 Shore 00 to about 90 Shore 00. In some embodiments, the durometer of the interface seal 130 may be between about 70 Shore 00 to about 80 Shore 00. Further, the interface seal 130 may have a modulus of elasticity that falls between a modulus of elasticity of the sealing member 116 and a modulus of elasticity of the tissue site 102 and/or the epidermis 106.

The interface seal 130 may have a width between about 10 millimeters to about 30 millimeters. In some embodiments, the width of the interface seal 130 may be about 20 millimeters. The width of the interface seal 130 may be directed, oriented, or adapted for positioning along a surface of the tissue site 102. In some embodiments, the width of the interface seal 130 may extend beyond the edge 121 of the dressing bolster 114 by about 10 millimeters and also overlap the second, inward-facing side 122 of the dressing bolster 114 by about 10 millimeters. Thus, the interface seal 130 may straddle the edge or periphery 121 of the dressing bolster 114, or otherwise extend beyond the periphery 121 of the dressing bolster 114. In other embodiments (not shown), the dressing bolster 114 may entirely overlap the interface seal 130.

The interface seal 130 may have a thickness between about 0.3 millimeters to about 2.5 millimeters. In some embodiments, the thickness of the interface seal 130 may be between about 0.7 millimeters to about 1.25 millimeters. The thickness of the interface seal 130 may be perpendicular to the width of the interface seal 130 and the tissue site 102. Other dimensions for the interface seal 130 are possible.

The interface seal 130 may be deployed by hand or extruded from an applicator, such as a syringe, prior to application of the dressing assembly 112 to the tissue site 102. Sealing materials suitable for application by extrusion may include water soluble gums such as xanthan, guar, or cellulose, and thick greases, such as silicones. In other embodiments, the interface seal 130 may be bonded in any suitable manner, such as, for example, by a heat bond, to the dressing assembly 112 during manufacture. In some embodiments, the interface seal 130 may have a ring-like or annular shape. In other embodiments, the interface seal 130 may be linear. Further, in some embodiments, the interface seal 130 may comprise one or more discrete members, including linear members, which may be formed into a ring-like or annular shape.

The interface seal 130 may be coupled directly to the dressing assembly 112, or coupled with an attachment device, such as an acrylic adhesive, cement, or other coupling device. In some embodiments, the interface seal 130 may be coupled to the second inward-facing side 122 of the dressing bolster 114, and/or to an adjacent layer, such as the second, inward facing side 128 of the comfort layer 124. Further, in some embodiments, the interface seal 130 may be adapted to be positioned between the comfort layer 124 and the tissue site 102, and/or tissue around the tissue site 102, such as the epidermis 106. Thus, in some embodiments, the comfort layer 124 may be coupled between the dressing bolster 114 and the interface seal 130.

In some embodiments, the interface seal 130 may include an absorbent. For example, the interface seal 130 may be a hydrocolloid comprising an absorbent, such as carboxy methyl cellulose (CMC). The absorbent may permit the interface seal 130 to absorb fluid from the tissue site 102 in addition to enhancing the fluid seal around the tissue site 102. The interface seal 130 including the absorbent may enhance the ability of the dressing assembly 112 to manage and direct fluid away from the tissue site 102 for keeping the tissue site 102 dry. For example, the dressing bolster 114 may have a thickness between the first side 120 and the second, inward-facing side 122 of the dressing bolster 114. The thickness of the dressing bolster 114 may define at least a portion of a thickness of the dressing assembly 112. The interface seal 130 may be adapted to be positioned between the dressing assembly 112 and the tissue site 102, as described above, and around or surrounding a circumference, perimeter, or periphery of the tissue site 102.

Relative to the dressing assembly 112, the interface seal 130 may be positioned, for example, around, on, or at the edge or periphery 121 of the dressing bolster 114 and/or the comfort layer 124. Further, the interface seal 130 may be positioned around or surrounding a circumference of the dressing bolster 114 and/or the comfort layer 124. Further, the interface seal 130 may be positioned around at least a portion of the dressing bolster 114 or the comfort layer 124 that is configured to be positioned directly against or in direct contact with the tissue site 102. At least a portion of the dressing bolster 114 and/or the comfort layer 124 may be exposed and configured to be positioned directly against the tissue site 102 when the interface seal 130 is positioned on the dressing assembly 112. Further, in such embodiments, the interface seal 130 may surround the exposed portion of the dressing bolster 114 and/or the comfort layer 124.

The absorbent in the interface seal 130 may wick or draw fluid in a lateral direction within the dressing assembly 112, normal to the thickness of the dressing bolster 114, and toward the edge or periphery 121 of the dressing bolster 114 for absorption in the interface seal 130. Thus, fluid from the tissue site 102 may be wicked or otherwise drawn in a lateral direction along the surface of the tissue site 102 toward the edge or periphery 121 of the dressing bolster 114 and into the interface seal 130. Further, fluid from the tissue site 102 may also flow through the thickness of the dressing assembly 112 and the dressing bolster 114 at least by operation of the manifold material comprising the dressing bolster 114, described above.

Referring to FIGS. 2-4, in some embodiments, the dressing assembly 112 may include a base layer 132. The use and configuration of the base layer 132 in the dressing assembly 112 may be beneficial for reducing the formation, size, and appearance of scars by, for example, increasing temperature and hydration levels at the tissue site 102. The base layer 132 may also enhance the ability of the dressing assembly 112 to impart apposition force to the tissue site 102, for example, for closing the incision 104 or otherwise contracting a portion of the tissue site 102. The base layer 132 may be configured to be coupled to the dressing bolster 114 and/or tissue around the tissue site 102 with an attachment device, such as an adhesive 136. In some embodiments, a portion of the base layer 132 may be configured to be coupled to the first side 120 of the dressing bolster 114.

The base layer 132 may include a base layer flange 152 configured to extend beyond the periphery 121 of the dressing bolster 114, for example, for coupling to tissue around or surrounding the tissue site 102. In some embodiments, the base layer flange 152 may be configured to be positioned in direct contact with tissue around or surrounding the tissue site 102, such as the epidermis 106. Further, the base layer flange 152 may be positioned around or surrounding a central region 156 of the base layer 132. Thus, in some embodiments, the base layer flange 152 may define, form, or be positioned at, a periphery of the base layer 132. Further, the base layer flange 152 may be configured to be positioned around the periphery 121 of the dressing bolster 114. In some embodiments, the base layer flange 152 may be configured to substantially or entirely surround the periphery 121 of the dressing bolster 114.

The base layer 132 may include corners 158 and edges 159. The corners 158 and the edges 159 may be part of the base layer flange 152. One of the edges 159 may meet another of the edges 159 to define one of the corners 158. Further, the base layer 132 may include a plurality of apertures 160 disposed through the base layer 132. In some embodiments, the apertures 160 may be disposed through the central region 156 of the base layer 132, for example, to facilitate fluid communication with the dressing bolster 114 and/or to couple the base layer 132 to the dressing bolster 114. In some embodiments, the apertures 160 may be disposed through the base layer flange 152, for example, to facilitate coupling the base layer 132 to tissue around or surrounding the tissue site 102 as described below.

The central region 156 of the base layer 132 may be positioned adjacent to or proximate to the dressing bolster 114, and the base layer flange 152 may be positioned adjacent to or proximate to tissue surrounding the tissue site 102. In this manner, the base layer flange 152 may be positioned around or surrounding the dressing bolster 114. Further, the apertures 160 in the base layer 132 may be in fluid communication with the dressing bolster 114 and tissue around or surrounding the tissue site 102.

The apertures 160 in the base layer 132 may have any shape, such as, for example, circles, squares, stars, ovals, polygons, slits, complex curves, rectilinear shapes, triangles, or other shapes. The apertures 160 may be formed by cutting, by application of local RF energy, or other suitable techniques for forming an opening. Each of the apertures 160 of the plurality of apertures 160 may be substantially circular in shape, having a diameter and an area. The area of each of the apertures 160 may refer to an open space or open area defining each of the apertures 160. The diameter of each of the apertures 160 may define the area of each of the apertures 160. The area of the apertures 160 described in the illustrative embodiments herein may be substantially similar to the area in other embodiments (not shown) for the apertures 160 that may have non-circular shapes.

The diameter of each of the apertures 160 may be substantially the same, or each of the diameters may vary depending, for example, on the position of the aperture 160 in the base layer 132. For example, the diameter of the apertures 160 in the base layer flange 152 may be larger than the diameter of the apertures 160 in the central region 156 of the base layer 132. The diameter of each of the apertures 160 may be between about 1 millimeter to about 50 millimeters. In some embodiments, the diameter of each of the apertures 160 may be between about 1 millimeter to about 20 millimeters. The apertures 160 may have a uniform pattern or may be randomly distributed on the base layer 132. Further, in some embodiments, an aperture 160 b positioned at the corners 158 may be smaller than an aperture 160 a positioned in the central region 156. In some embodiments, the apertures 160 a may have a diameter between about 9.8 millimeters to about 10.2 millimeters, and the apertures 160 b may have a diameter between about 7.75 millimeters to about 8.75 millimeters.

The base layer 132 may be a soft, pliable material. For example, the base layer 132 may comprise a silicone gel, a soft silicone, hydrocolloid, hydrogel, polyurethane gel, polyolefin gel, hydrogenated styrenic copolymer gels, a foamed gel, a soft closed cell foam such as polyurethanes and polyolefins coated with an adhesive described below, polyurethane, polyolefin, or hydrogenated styrenic copolymers. The base layer 132 may have a thickness between about 500 microns (μm) and about 1000 microns (μm). In some embodiments, the base layer 132 may have a stiffness between about 5 Shore 00 to about 80 Shore 00. The base layer 132 may be comprised of hydrophobic or hydrophilic materials. The base layer 132 may be operable to transmit forces, such as, for example, an apposition force, proximate to the tissue site 102, and to enhance a fluid seal with the tissue site 102 as described herein.

In some embodiments (not shown), the base layer 132 may be a hydrophobic-coated material. For example, the base layer 132 may be formed by coating a spaced material, such as, for example, woven, nonwoven, molded, or extruded mesh with a hydrophobic material. The hydrophobic material for the coating may be a soft silicone, for example. In this manner, the spaced material may provide openings analogous to the apertures 160 described above.

The adhesive 136 may be in fluid communication with the apertures 160 in at least the base layer flange 152. In this manner, the adhesive 136 may be in fluid communication with tissue surrounding the tissue site 102 through the apertures 160 in the base layer 132. As described below and shown in FIG. 3, the adhesive 136 may extend or be pressed through the plurality of apertures 160 to contact the epidermis 106 for securing the dressing assembly 112 to, for example, tissue surrounding the tissue site 102. The apertures 160 may provide sufficient contact of the adhesive 136 to the epidermis 106 to secure the dressing assembly 112 about the tissue site 102. However, the configuration of the apertures 160 and the adhesive 136, described below, may permit release and repositioning of the dressing assembly 112 about the tissue site 102.

Referring to FIG. 4, at least one of the apertures 160 a in the base layer flange 152 may be positioned at the edges 159 and may have an interior cut open or exposed at the edges 159 and in fluid communication in a lateral direction with an exterior of the edges 159. The lateral direction may refer to a direction in the same plane as the base layer 132. Thus, the exposed interior of the apertures 160 a at the edges 159 may permit the adhesive 136 to flow around and exterior to the edges 159 for enhancing the adhesion of the edges 159 around the tissue site 102.

The size and configuration of the apertures 160 may be designed to control the adherence of the dressing assembly 112 at the tissue site 102. For example, the size and number of the apertures 160 b in the corners 158 may be adjusted as necessary, depending on the chosen geometry of the corners 158, to maximize the exposed surface area of the adhesive 136. Further, the apertures 160 b at the corners 158 may be fully housed within the base layer 132, substantially precluding fluid communication in a lateral direction exterior to the corners 158. The apertures 160 b at the corners 158 being fully housed within the base layer 132 may substantially preclude fluid communication of the adhesive 136 exterior to the corners 159, and may provide improved handling of the dressing 124 during deployment at the tissue site 102. Further, the exterior of the corners 158 being substantially free of the adhesive 136 may increase the flexibility of the corners 158 to enhance comfort. Similar to the apertures 160 b in the corners 158, any of the apertures 160 may be adjusted in size and number to maximize the surface area of the adhesive 136 in fluid communication through the apertures 160 for a particular application or geometry of the base layer 132.

The adhesive 136 may be a medically-acceptable adhesive. The adhesive 136 may also be flowable. For example, the adhesive 136 may comprise an acrylic adhesive, rubber adhesive, high-tack silicone adhesive, polyurethane, or other adhesive substance. In some embodiments, the adhesive 136 may be a pressure-sensitive adhesive comprising an acrylic adhesive with coating weight of 15 grams/m² (gsm) to 70 grams/m² (gsm). In some embodiments, the adhesive 136 may be a layer having substantially the same shape as the base layer 132. In some embodiments, the adhesive 136 may be continuous layer. In other embodiments, the adhesive 136 may be discontinuous. For example, the adhesive 136 may be a patterned coating on a carrier layer, such as, for example, a side of the sealing member 116 adapted to face the epidermis 106. Further, discontinuities in the adhesive 136 may be sized to control the amount of the adhesive 136 extending through the apertures 160 in the base layer 132 to reach the epidermis 106. The discontinuities in the adhesive 136 may also be sized to enhance the Moisture Vapor Transfer Rate (MVTR) of the dressing assembly 112.

Factors that may be utilized to control the adhesion strength of the dressing assembly 112 may include the diameter and number of the apertures 160 in the base layer 132, the thickness of the base layer 132, the thickness and amount of the adhesive 136, and the tackiness of the adhesive 136. An increase in the amount of the adhesive 136 extending through the apertures 160 may correspond to an increase in the adhesion strength of the dressing assembly 112. A decrease in the thickness of the base layer 132 may correspond to an increase in the amount of adhesive 136 extending through the apertures 160. Thus, the diameter and configuration of the apertures 160, the thickness of the base layer 132, and the amount and tackiness of the adhesive 136 utilized may be varied to provide a desired adhesion strength for the dressing assembly 112. In some embodiments, the thickness of the base layer 132 may be about 200 microns, the adhesive 136 may have a thickness of about 30 microns and a tackiness of 2000 grams per 25 centimeter wide strip, and the diameter of the apertures 160 a in the base layer 132 may be about 10 millimeters.

In some embodiments, the tackiness of the adhesive 136 may vary in different locations of the base layer 132. For example, in locations of the base layer 132 where the apertures 160 are comparatively large, such as the apertures 160 a, the adhesive 136 may have a lower tackiness than other locations of the base layer 132 where the apertures 160 are smaller, such as the apertures 160 b. In this manner, locations of the base layer 132 having larger apertures 160 and lower tackiness adhesive 136 may have an adhesion strength comparable to locations having smaller apertures 160 and higher tackiness adhesive 136.

The sealing member 116 may have a periphery 164 and a central region 168. The periphery 164 of the sealing member 116 may be positioned proximate to the base layer flange 152. The adhesive 136 may be positioned at least between the periphery 164 of the sealing member 116 and the base layer flange 152. In some embodiments, a portion of the periphery 164 of the sealing member 116 may extend beyond the base layer flange 152 and into direct contact with tissue surrounding the tissue site 102. Thus, the adhesive 136 may also be positioned at least between the periphery 164 of the sealing member 116 and tissue, such as the epidermis 106, surrounding the tissue site 102. In some embodiments, the adhesive 136 may be disposed on a surface of the sealing member 116 adapted to face the tissue site 102 and the base layer 132.

In some embodiments, the sealing member 116 may be configured to extend beyond the periphery 121 of the dressing bolster 114. Further, in some embodiments, the sealing member 116 may be configured to cover at least a portion of the first side 120 of the dressing bolster 114 and to extend beyond the periphery 121 of the dressing bolster 114 proximate to the base layer flange 152. In some embodiments, the adhesive 136 may be positioned between the sealing member 116 and the base layer 132 such that the adhesive 136 is in fluid communication with at least the apertures 160 in the base layer flange 152. Thus, the adhesive 136 may be positioned at least between the sealing member 116 and the base layer flange 152. Further, in some embodiments, the adhesive 136 may be configured to be in fluid communication with tissue around or surrounding the tissue site 102 through the apertures 160 in the base layer flange 152.

The sealing member 116 may be formed from any material that allows for a fluid seal. A fluid seal may be a seal adequate to maintain reduced pressure at a desired site given the particular reduced pressure source or system involved. The sealing member 116 may comprise, for example, one or more of the following materials: hydrophilic polyurethane; cellulosics; hydrophilic polyamides; polyvinyl alcohol; polyvinyl pyrrolidone; hydrophilic acrylics; hydrophilic silicone elastomers; an INSPIRE 2301 material from Expopack Advanced Coatings of Wrexham, United Kingdom having, for example, an MVTR (inverted cup technique) of 14400 g/m²/24 hours and a thickness of about 30 microns; a thin, uncoated polymer drape; natural rubbers; polyisoprene; styrene butadiene rubber; chloroprene rubber; polybutadiene; nitrile rubber; butyl rubber; ethylene propylene rubber; ethylene propylene diene monomer; chlorosulfonated polyethylene; polysulfide rubber; polyurethane (PU); EVA film; co-polyester; silicones; a silicone drape; a 3M Tegaderm® drape; a polyurethane (PU) drape such as one available from Avery Dennison Corporation of Pasadena, Calif.; polyether block polyamide copolymer (PEBAX), for example, from Arkema, France; Expopack 2327; or other appropriate material.

The sealing member 116 may be vapor permeable and liquid impermeable, thereby allowing vapor and inhibiting liquids from exiting the sealed space 119. In some embodiments, the sealing member 116 may be a flexible, breathable film, membrane, or sheet having a high moisture vapor transfer rate (MVTR) of, for example, at least about 300 g/m² per 24 hours. In other embodiments, a low or no vapor transfer drape might be used. The sealing member 116 may comprise a range of medically suitable films having a thickness between about 15 microns (μm) to about 50 microns (μm).

FIGS. 5A-5C provide an illustrative embodiment of a method for assembling the dressing assembly 112 in stages at the tissue site 102, such as the incision 104. In FIG. 5A, a closure device 502, such as, for example, stitches 504, may close the incision 104. Other closure devices 502, such as epoxy or staples may be utilized to close the incision 104. The tissue site 102 may include a first portion 172 and second portion 174. The first portion 172 of the tissue site 102 may be positioned on an opposite side of the incision 104 from the second portion 174 of the tissue site 102.

Referring to FIG. 5B, after the incision 104 is closed or prepared as described above, the dressing assembly 112 may be disposed proximate to the incision 104. For example, the dressing bolster 114 of the dressing assembly 112 may be positioned across the incision 104 between the first portion 172 and the second portion 174 of the tissue site 102. The comfort layer 124 may be positioned in contact with the tissue site 102 between the dressing bolster 114 and the tissue site 102. The dressing bolster 114 may be in fluid communication with the tissue site 102 through the comfort layer 124. The interface seal 130 may be positioned at the periphery 121 of the dressing bolster 114 and between the dressing bolster 114 and the tissue site 102. The interface seal 130 may be positioned around a portion of the comfort layer 124 positioned in direct contact with the tissue site 102. The portion of the comfort layer 124 in direct contact with the tissue site may be free of the interface seal 130 such that fluid communication is permitted through the comfort layer 124 to the dressing bolster 114. In other embodiments, elements may be added or omitted as desired. For example, in some embodiments, the comfort layer 124 may be omitted and the dressing bolster 114 may be positioned at the tissue site 102 as described for the comfort layer 124.

Referring to FIG. 5C, the sealing member 116 may be disposed over or covering the dressing bolster 114 and a portion of the epidermis 106 to form the sealed space 119 between the sealing member 116 and the incision 104. The sealing member 116, the base layer 132, and the adhesive 136 may be deployed together at the tissue site 102 as an assembly or kit. Once in position, the adhesive 136 may be pressed through the apertures 160 in the base layer 132 into contact with the dressing bolster 114 and the epidermis 106. The adhesive 136 may be pressed through the apertures 160 in the base layer 132, for example, by applying pressure to an exterior surface of the sealing member 116. Pressure may be applied to the exterior surface of the sealing member 116 by hand, for example, to manipulate or force the adhesive 136 through the apertures 160 in the base layer 132. An aperture (not shown) may be formed or preformed in the sealing member 116 to provide fluid communication between the sealed space 119 and the reduced-pressure source 144, such as, for example, through the conduit interface 138 and the delivery conduit 148.

Reduced pressure may be applied to the tissue site 102, and fluid may be extracted from the tissue site 102 and into the dressing assembly 112. A portion of the fluid from the tissue site 102 may be absorbed into the interface seal 130. Further, the fluid from the tissue site 102 may be wicked or otherwise communicated in a lateral direction within the dressing assembly 112 toward the interface seal 130. The application of reduced pressure to the sealed space 119 may also contract the dressing bolster 114, imparting an inward force or an apposition force to the tissue site 102 that may move the first portion 172 of the tissue site 102 toward the second portion 174 of the tissue site 102. The movement of the first portion 172 toward or closer to the second portion 174 may provide closure of the incision 104 at the tissue site 102. The inward force or apposition force may be imparted to the tissue site 102 through the configuration of the base layer 132 and the interface seal 130 disclosed herein.

Referring to FIG. 6, in some embodiments, a portion of the base layer 132 may be configured to be positioned on or coupled to the second, inward-facing side 122 of the dressing bolster 114. For example, the central region 156 of the base layer 132 may be positioned on or coupled to the second, inward-facing side 122 of the dressing bolster 114. In some embodiments, the base layer 132 may be positioned between the dressing bolster 114 and the tissue site 102. Further, in some embodiments, the base layer 132 may be positioned or coupled relative to the dressing bolster 114 through other elements, such as, for example, the comfort layer 124 and/or the interface seal 130. For example, the comfort layer 124 may be positioned between the second, inward-facing side 122 of the dressing bolster 114 and the base layer 132. In other embodiments, the base layer 132 may be directly positioned on or directly coupled to the dressing bolster 114.

In some embodiments, the base layer 132 may include a bridge 176 configured to extend across or to cover a portion of the tissue site 102, such as, for example, the incision 104. In some embodiments, the bridge 176 may be configured to be positioned in direct contact with the incision 104, or other desired portion of the tissue site 102. In some embodiments, the bridge 176 may be a solid or continuous portion of the base layer 132 that is free of the apertures 160. Further, in some embodiments, the bridge 176 or other portion of the base layer 132 may be positioned in direct contact with scar tissue at the tissue site 102, or an area of the tissue site 102 prone to formation of scar tissue.

In some embodiments, the bridge 176 may be configured to extend between the first portion 172 of the tissue site 102 and the second portion 174 of the tissue site 102. The first portion 172 and the second portion 174 of the tissue site 102 may be, for example, on opposite sides of the incision 104, or other desired area of the tissue site 102.

In some illustrative embodiments, a method for treating the tissue site 102 may include providing the dressing bolster 114 having the first side 120, the second side 122, and the edge 121 defining the outer boundary of the dressing bolster 114. Further, the method may include positioning the interface seal 130 between the second side 122 of the dressing bolster 114 and the tissue site 102 at the edge 121 of the dressing bolster 114. Further, the method may include coupling the base layer 132 to the dressing bolster 114 and to a tissue, such as the epidermis 106, around the tissue site 102. Further, the method may include covering the first side 120 of the dressing bolster 114 with the sealing member 116 to form the sealed space 119 relative to the tissue site 102. The dressing bolster 114 may be positioned in the sealed space 119.

In some embodiments, the method may include positioning the second side 122 of the dressing bolster 114 facing the tissue site 102. Further, in some embodiments, the method may include positioning the comfort layer 124 between the second side 122 of the dressing bolster 114 and the interface seal 130. Further, in some embodiments, coupling the base layer 132 may include coupling the base layer 132 to a tissue around the edge 121 of the dressing bolster 114.

In some embodiments, at least a portion of the second side 122 of the dressing bolster 114 may be free of the interface seal 130 and positioned in fluid communication with the tissue site 102. Further, in some embodiments, the interface seal 130 may be positioned around the periphery 121 of the dressing bolster 114 and the tissue site 102. Further, in some embodiments, the interface seal 130 may substantially surround the periphery 121 of the dressing bolster 114 and the tissue site 102.

In some embodiments, the base layer 132 may include the plurality of apertures 160, and the step of coupling the base layer 132 may include positioning the adhesive 136 in fluid communication with a tissue around the tissue site 102 though the apertures 160 in the base layer 132. Further, in some embodiments, the method may include positioning the adhesive 136 between the sealing member 116 and the base layer 132. Further, in some embodiments, the method may include pressing the adhesive 136 through the plurality of apertures 160 in the base layer 132 into contact with a tissue around the tissue site 102. Further, in some embodiments, the base layer 132 may include the base layer flange 152 that may extend beyond the edge 121 of the dressing bolster 114 and into contact with a tissue around the tissue site 102. The plurality of apertures 160 may be disposed at least through the base layer flange 152.

In some embodiments, the method may include extracting fluid from the tissue site 102. Further, in some embodiments, the method may include drawing the first portion 172 of the tissue site 102 toward the second portion 174 of the tissue site 102. In some embodiments, drawing the first portion 172 of the tissue site 102 toward the second portion 174 of the tissue site 102 may include contracting the dressing bolster 114 by applying reduced pressure to the dressing bolster 114 and the sealed space 119. In some embodiments, contracting the dressing bolster 114 may impart an inward force between the first portion 172 of the tissue site 102 and the second portion 174 of the tissue site 102 through the interface seal 130 and the base layer 132.

Referring to FIG. 7, provided is a graph illustrating a plot of apposition force versus time for each of three dressings during intermittent application of reduced pressure at −125 mm Hg to each of the dressings. Two of the plots, designated as Baseline 1 and Baseline 2, illustrate the apposition force for each of two known or prior art dressings to establish two sets of baseline data for comparison. The third plot, designated as Improved Dressing Assembly, illustrates the apposition force for the dressing assembly 112 according to this disclosure, including the base layer 132 and the interface seal 130. As shown, the dressing assembly 112, including the base layer 132 and the interface seal 130, exhibited an increased apposition force at the tissue site compared to Baseline 1 and Baseline 2. Thus, the data shows that the disclosed configuration of the dressing assembly 112, including the base layer 132 and the interface seal 130, may provide an increase in the apposition force that may be imparted to a tissue site. Further, the use and configuration of the base layer 132 in the dressing assembly 112 as described herein may increase the temperature and hydration at the tissue site 102, which may be beneficial for reducing the formation of scar tissue, and the size and appearance of any existing scar tissue.

Although the subject matter of this disclosure has been provided by way of example in the context of certain illustrative, non-limiting embodiments, various changes, substitutions, permutations, and alterations can be made without departing from the scope of this disclosure as defined by the appended claims. Any feature described in connection to any one embodiment may also be applicable to any other embodiment. As such, the benefits and advantages described above may relate to one embodiment or may relate to several embodiments. Further, the steps of the methods described herein may be carried out in any suitable order, or simultaneously where appropriate. 

1.-24. (canceled)
 25. A dressing assembly, comprising: a dressing bolster comprising a first side, a second side, and a periphery; an interface seal coupled at the periphery of the dressing bolster; a base layer comprising a base layer flange configured to be coupled to the dressing bolster and to extend beyond the periphery of the dressing bolster; a sealing member configured to cover at least a portion of the first side of the dressing bolster; and an adhesive positioned at least between the sealing member and the base layer flange.
 26. The dressing assembly of claim 25, wherein the dressing bolster comprises foam.
 27. The dressing assembly of claim 25, wherein the interface seal comprises a hydrocolloid.
 28. The dressing assembly of claim 25, wherein the base layer comprises silicone.
 29. The dressing assembly of claim 25, wherein the sealing member comprises a liquid impermeable film.
 30. The dressing assembly of claim 25, further comprising a comfort layer including a first side and a second side, the first side of the comfort layer coupled to the second side of the dressing bolster.
 31. The dressing assembly of claim 30, wherein the interface seal is coupled to the second side of the comfort layer.
 32. The dressing assembly of claim 30, wherein the comfort layer is coupled between the dressing bolster and the interface seal.
 33. The dressing assembly of claim 25, wherein the interface seal is coupled to the second side of the dressing bolster.
 34. The dressing assembly of claim 25, wherein the interface seal has a hardness between about 70 to about 80 Shore, type
 00. 35. The dressing assembly of claim 25, wherein the interface seal has a thickness between about 0.7 millimeters to about 1.25 millimeters.
 36. The dressing assembly of claim 25, wherein a portion of the second side of the dressing bolster is free of the interface seal.
 37. The dressing assembly of claim 25, wherein the periphery of the dressing bolster defines an outer boundary of the dressing bolster.
 38. The dressing assembly of claim 25, wherein the interface seal extends beyond the periphery of the dressing bolster.
 39. The dressing assembly of claim 25, wherein the base layer flange is configured to be positioned around the periphery of the dressing bolster.
 40. The dressing assembly of claim 25, wherein the base layer includes a plurality of apertures disposed through the base layer flange, and wherein the adhesive is in fluid communication with the apertures in the base layer flange.
 41. The dressing assembly of claim 25, wherein the sealing member is configured to extend beyond the periphery of the dressing bolster.
 42. The dressing assembly of claim 25, wherein the sealing member is configured to cover the first side of the dressing bolster and to extend beyond the periphery of the dressing bolster proximate to the base layer flange.
 43. A method for treating a tissue site, comprising: providing a dressing bolster having a first side, a second side, and an edge defining an outer boundary of the dressing bolster; positioning an interface seal between the second side of the dressing bolster and the tissue site at the edge of the dressing bolster; coupling a base layer to the dressing bolster and to a tissue around the tissue site; covering the first side of the dressing bolster with a sealing member to form a sealed space relative to the tissue site.
 44. The method of claim 43, further comprising positioning the second side of the dressing bolster facing the tissue site.
 45. The method of claim 43, further comprising positioning a comfort layer between the second side of the dressing bolster and the interface seal.
 46. The method of claim 43, wherein coupling the base layer comprises coupling the base layer to a tissue around the edge of the dressing bolster.
 47. The method of claim 43, wherein the dressing bolster is positioned in the sealed space.
 48. The method of claim 43, wherein at least a portion of the second side of the dressing bolster is free of the interface seal and positioned in fluid communication with the tissue site.
 49. The method of claim 43, wherein the interface seal is positioned around a periphery of the dressing bolster and the tissue site.
 50. The method of claim 43, wherein the interface seal substantially surrounds a periphery of the dressing bolster and the tissue site.
 51. The method of claim 43, wherein the base layer comprises a plurality of apertures, wherein coupling the base layer comprises positioning an adhesive in fluid communication with the tissue around the tissue site through the apertures in the base layer.
 52. The method of claim 51, further comprising positioning the adhesive between the sealing member and the base layer.
 53. The method of claim 51, further comprising pressing the adhesive through the plurality of apertures in the base layer into contact with the tissue around the tissue site.
 54. The method of claim 51, wherein the base layer comprises a base layer flange extending beyond the edge of the dressing bolster and into contact with the tissue around the tissue site, the plurality of apertures disposed at least through the base layer flange.
 55. The method of claim 43, further comprising extracting fluid from the tissue site.
 56. The method of claim 43, further comprising drawing a first portion of the tissue site toward a second portion of the tissue site.
 57. The method of claim 56, wherein drawing the first portion of the tissue site toward the second portion of the tissue site comprises contracting the dressing bolster by applying reduced pressure to the dressing bolster and the sealed space.
 58. The method of claim 57, wherein contracting the dressing bolster imparts an inward force between the first portion of the tissue site and the second portion of the tissue site through the interface seal and the base layer.
 59. The method of claim 43, wherein the interface seal comprises a hydrocolloid.
 60. The method of claim 43, wherein the base layer comprises silicone.
 61. The method of claim 43, wherein the sealing member comprises a liquid impermeable film.
 62. The method of claim 43, wherein the dressing bolster comprises foam.
 63. A system for treating a tissue site, comprising: a manifold having a first side, a second side, and a periphery; an interface seal positioned at the periphery of the manifold and on the second side of the manifold; a base layer comprising a base layer flange configured to extend beyond the periphery of the manifold; and a drape configured to cover the first side of the manifold and to create a sealed space relative to the tissue site.
 64. The system of claim 63, wherein the periphery of the manifold defines a lateral boundary of the first side and the second side of the manifold.
 65. The system of claim 63, wherein at least a portion of the drape is configured to extend beyond the periphery of the manifold proximate to the base layer flange.
 66. The system of claim 63, wherein a portion of the base layer is configured to be coupled to the manifold.
 67. The system of claim 63, further comprising an interface layer positioned on the second side of the manifold.
 68. The system of claim 63, wherein the interface seal is positioned around the periphery of the manifold.
 69. The system of claim 63, wherein the interface seal is configured to extend beyond the periphery of the manifold.
 70. The system of claim 63, wherein the base layer comprises a plurality of apertures disposed through the base layer, the system further comprising an adhesive positioned between the drape and the base layer.
 71. The system of claim 70, wherein the adhesive is in fluid communication with the apertures in the base layer.
 72. The system of claim 63, wherein the base layer flange comprises a plurality of apertures disposed through the base layer flange, the system further comprising an adhesive positioned between the drape and the base layer flange.
 73. The system of claim 63, wherein the manifold comprises foam.
 74. The system of claim 63, wherein the interface seal comprises a hydrocolloid.
 75. The system of claim 63, wherein the drape comprises a liquid impermeable film.
 76. The system of claim 63, further comprising a reduced-pressure source configured to be coupled in fluid communication with the sealed space.
 77. A dressing assembly, comprising: a manifold comprising a first side, a second side, and a periphery; an interface seal coupled at the periphery of the manifold; and a base layer comprising a base layer flange configured to extend beyond the periphery of the manifold.
 78. (canceled) 